ASTRAZENECA DL-,25 SP.ADR
ASTRAZENECA DL-,25 SP.ADR/ US0463531089 /
ZEGA
|
23/01/2025 15:39:52
|
Chg.
+0.50
|
Volume |
Bid17:44:13 |
Ask17:44:13 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
66.00EUR
|
+0.76%
|
5
Turnover: 330 |
65.50Bid Size: 390 |
66.00Ask Size: 380 |
204.16 bill.EUR |
- |
- |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
| CEO |
| Pascal Soriot |
| Management board |
| Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Jeff Pott, Iskra Reic, Sharon Barr |
| Supervisory board |
| Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg, Anna Manz, Rene Haas |